Trial Profile
FDHT-PET to Visualize the Effect on the Androgen Receptor Level by Bicalutamide
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Bicalutamide (Primary)
- Indications Advanced breast cancer
- Focus Pharmacodynamics
- 17 Dec 2020 Results published in the European Journal of Cancer.
- 26 Nov 2019 Status changed from active, no longer recruiting to completed.
- 10 Sep 2019 Planned End Date changed from 1 Aug 2019 to 1 Dec 2019.